20% subcutaneous immunoglobulin regulatory update

FDA approved a BLA for Cuvitru 20% subcutaneous immunoglobulin from Shire to treat primary immunodeficiency in patients ages >=2. The company said it expects to launch Cuvitru “in the coming weeks.” I...